Hereditary Angioedema Market Trends, Analysis and Forecast till 2030

February 2020
Copyright © PROPHECY MARKET INSIGHTS 2019, All Rights Reserved
Global Hereditary Angioedema Market:
Industry, Size, Share, Growth, Trends and
Forecast, 2019–2029

Report Snippet
Copyright © PROPHECY MARKET INSIGHTS 2019, All Rights Reserved 2
Chapter 1 : Table of Contents
Chapter 3: Market Dynamics
Chapter 4: Global Hereditary Angioedema Market,
By Drug Class
Chapter 2: Market Purview
By Route of Administration
By Region
Chapter 8: Competitive Analysis
Chapter 9: Company Profiles Investment Outlook
Future of the Market
By Distribution Channel

Table of Contents

Table of Content
Sr. No. Content
1.0 Chapter 1
Research Methodology
Research Objective and Assumption
Research Process
Scope & Coverage
Currency Conversion Rate
2.0 Chapter 2
2.1 Market Purview
2.2 Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
Opportunity Map Analysis
Market at Glance
3.0 Chapter 3

Table of Content
Sr. No. Content
Drivers
Restrains
Opportunities
Trends
DR Impact Analysis
PEST Analysis
Porter’s Five Forces Analysis
Pipeline Analysis
Introduction of New Products/Approvals
4.0 Chapter 4
4.0.1 Global Hereditary Angioedema Market Value (US$ Mn), By Drug Class
Segment Overview
Market Value and Forecast (US$ Mn), and Share (%) Analysis, 2018 – 2029
Y-o-Y Growth (%) Analysis, 2019 – 2029
4.1 C1 Esterase Inhibitor
Overview

Table of Content
Sr. No. Content
Market Value and Forecast (US$ Mn), and Y-o-Y Growth (%) Analysis, 2018 – 2029
4.2 Kallikrein Inhibitor
Overview
4.3 Bradykinin Receptor
Overview
4.4 Oral
Overview
5.0 Chapter 5
5.0.1 Global Hereditary Angioedema Market Value (US$ Mn), By Route of Administration
Segment Overview
5.1 Subcutaneous

Table of Content
Sr. No. Content
Overview
5.2 Intravenous
Overview
5.3 Oral
Overview
6.0 Chapter 6
6.0.1 Global Hereditary Angioedema Market Value (US$ Mn), By Distribution Channel
Segment Overview
6.1 Hospital Pharmacies
Overview

Table of Content
Sr. No. Content
6.2 Retail Pharmacies
Overview
6.3 Online Pharmacies
Overview
7.0 Chapter 7
7.0.1 Global Hereditary Angioedema Market Value (US$ Mn), By Region
Overview
Market Share (%) and BPS Analysis, By Region
7.1 North America
Overview
Market Value and Forecast (US$ Mn), 2018 – 2029
North America Hereditary Angioedema Market, By Drug Class

Table of Content
Sr. No. Content
North America Hereditary Angioedema Market, By Route of Administration
North America Hereditary Angioedema Market, By Distribution Channel
North America Hereditary Angioedema Market, By Country
U.S.
Canada
7.2 Europe
Overview
Europe Hereditary Angioedema Market, By Drug Class
Europe Hereditary Angioedema Market, By Route of Administration
Europe Hereditary Angioedema Market, By Distribution Channel
Europe Hereditary Angioedema Market, By Country
Germany

Table of Content
Sr. No. Content
UK
France
Russia
Italy
Rest of Europe
7.3 Asia Pacific
Overview
Asia Pacific Hereditary Angioedema Market, By Drug Class
Asia Pacific Hereditary Angioedema Market, By Route of Administration
Asia Pacific Hereditary Angioedema Market, By Distribution Channel

Table of Content
Sr. No. Content
Asia Pacific Hereditary Angioedema Market, By Country
China
India
Japan
South Korea
Rest of Asia-Pacific
7.4 Latin America
Overview
Latin America Hereditary Angioedema Market, By Drug Class
Latin America Hereditary Angioedema Market, By Route of Administration

Table of Content
Sr. No. Content
Latin America Hereditary Angioedema Market, By Distribution Channel
Latin America Hereditary Angioedema Market, By Country
Brazil
Mexico
Rest of Latin America
7.5 Middle East & Africa
Overview
Middle East & Africa Hereditary Angioedema Market, By Drug Class
Middle East & Africa Hereditary Angioedema Market, By Route of Administration
Middle East & Africa Hereditary Angioedema Market, By Distribution Channel
Middle East & Africa Hereditary Angioedema Market, By Country
GCC

Table of Content
Sr. No. Content
Israel
South Africa
Rest of Middle East & Africa
8.0 Chapter 8
Competitive Landscape
Competitive Overview
Heat Map Analysis
Market Presence and Specificity Analysis
9.0 Chapter 9
9.0.1 Company Profiles
9.1 CSL Behring
Company Overview

Table of Content
Sr. No. Content
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
9.2 Shire Plc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
9.3 Pharming Healthcare, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies

Table of Content
Sr. No. Content
9.4 BioCryst Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
9.5 Catalent Pharma Solutions
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
9.6 Ionis Pharmaceuticals, Inc
Company Overview
Product Portfolio
Key Highlights

Table of Content
Sr. No. Content
Financial Overview
Business Strategies
9.6 Arrowhead Pharmaceuticals
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
9.7 Adverum Biotechnologies
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
9.8 Attune Pharmaceuticals, Inc.
Company Overview

Table of Content
Sr. No. Content
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
10.0 Chapter 10
Investment Outlook
Future of Market
Appendix
Abbreviation
*The content/data is provided for illustration purpose only and is subject to change in the final version of the report

Notes
 The segmentation provided on the segmentation page is the actual/proposed segmentation for the target market
 Content and statistical data /values offered in the sample is primarily to provide an understanding of what we
offer in terms of style, content, and structure and may not necessarily to be related to actual for the requested
market
 Market value/revenue for the target market will be provided in the final version of the report
 The company names mentioned are those that are to be actually profiled in the final report
 The trailing slides that contain dummy data/hidden content for the target market is provided to gain a better
understanding of our competence, as well as a clearer view of how and what we offer in our report.
 The number of slides/pages provided for segment and region will be followed in a similar manner for remaining
segments of the target market.
 The values provided in the table’s, graphs, and figure’s are for illustration purpose only.
Points to Remember
Source: Prophecy Market Insights

About Us
19

About Us
20
Who we are:
Prophecy is a specialized market research, analytics, marketing
and business strategy, and solutions company that offer strategic
and tactical support to clients for making well-informed business
decisions and to identify and achieve high value opportunities in
the target business area. Also, we help our client to address
business challenges and provide best possible solutions to
overcome them and transform their business.
Prophecy’s expertize area covers Deployments, services, latest
trends, developments, market growth factors, and challenges
along with market forecast in various business areas such as
Healthcare, Pharmaceutical, Biotechnology, Information
Technology (IT), Subcutaneouss, Small and medium-sized
enterprises (SMEs), Chemical, Agriculture, Food and Beverage,
Energy, and Oil and Gas. We also offer various other services such
as, data mining, information management, and revenue
enhancement suggestions.
We are a team of dedicated and impassioned individuals,
who believe strongly in giving our very best to what we do
and we never return down from any challenge. At prophecy
we cater to industries, individuals, and organizations across
the globe and deliver our offerings in the shortest possible
turnaround time.
Our well defined approach ensures our clients will receive
unique competitive advantage, and secure and long lasting
results.
“WE BELIEVE IN LONG–TERM BUSINESS
RELATIONS FOR GROWTH AND SUCCESS”

A rich repository of syndicated
reports across 8 Industries
Dedicated Analyst
Working
More than 100+ Clients
worldwide including various
Fortune 500 Companies
Pioneer in adopting best
research practices to ensure
deeper insights
Top leadership having more
than
50 man years of experience
across varied industries
2+ years of industry
experience in delivering
valuable research Insights at
Global, Regional and Country
Level
About Us

Collection
of
Data
Collaboration
of Data
Identification
of data
Evaluation of
Market
Dynamics
Verification
and Analysis
2.This process consists
of gathering data,
accessing proprietary
databases, and reaching
out to key industry
participants that
operate in the market
across the value chain.
It also involves studying
several patterns in
the historical data and
comparing it with the
current scenario.
4. This is the final stage,
which involves both
quantity and quality
checks. Although the
process of data
verification is an integral
part of the research
process, all data points
and statistics and figures
are re-checked to uphold
their authenticity and
validity.
3.This stage involves the
validation of data and
arrival at actual statistics,
and evolution of the
market over the years. It
entails the study and
analyzes various segments
and verticals of the
market. An impact analysis
is also performed to
observe which factors will
affect the market in the
next few years.
1. This step involves identification of several primary
and secondary data research sources, including
Prophecy internal data sources.
The primary sources consist of in-depth discussions
and interviews with policy makers, industry experts,
and data evaluators, whereas secondary sources
include a thorough study of market journals, press
releases, annual reports, and government and non
government agencies websites.
This phase includes a detailed evaluation of several
factors that are likely to affect the market dynamics.
It involves a comprehensive assessment of major
market pain points, drivers, and trends.

Research Objective
To predict the
size of the
market
To offer wide ranging market
statistics with a detailed
classification along with the
market size of each segment
To analyze key
strengths,
opportunities,
and strategies of
major
companies
To outline and forecast the
Hereditary Angioedema market in
globally based on segmentation and
region
To study market
opportunities for
participants and
stakeholders by
identifying high
growth sectors in
the market
To provide comprehensive
information about factors that affect
market dynamics
To analyze several micro-market
indicators considering growth
factors, market prospects, and
strategic market contribution
To examine competitive scenarios
such as collaborations, mergers and
acquisitions, R&D activities, and
advanced developments

Research Process
PROJECT
SCOPE
PROJECT
KICKOFF
PRELIMINARY
RESEARCH
MARKET
ANALYSIS &
SEGMENTATION
REPORT
SYNTHESIS
REPORT
DELIVERY
POST-SALE
SERVICE

Global Market Size
Market/Revenue share of each key player in each
Deployment segment
Market/Revenue share of each key player in the
global market
Bottom-up Approach –
Collection of market related data and information
from primary and secondary sources, and data
analysis.
Primary Sources:
 Demand Side Key Opinion Leaders
 Supply Side Key Opinion Leaders
Secondary Sources:
 Annual Reports
 Financial Reports and Presentations
 Press Releases
 Research Journals
 Paid Data Sources
Market/Revenue share split by each market segment
such as by Deployment Fracturing Fluids/Fracturing
Fluids sector/end user
Market/Revenue share split by each region and
country in the global market
Top-down Approach –
Market size and analysis validation through primary
and secondary research participants and key opinion
leaders.
Primary Sources:
 Demand Side Key Opinion Leaders
 Supply Side Key Opinion Leaders
Secondary Sources:
 Annual Reports
 Financial Reports and Presentations
 Press Releases
 Research Journals
 Paid Data Sources

Definition and Scope – Prophecy Market Insights provide the market definition to
understand the target Deployment/service and provide the market scope to
understand the report coverage after thoroughly understanding of target market
and market specific requirements.
Primary Research – We formulates a detailed discussion guide to perform primary
research. In primary research collection of data is performed through telephonic
interview, E-mail questionnaire’s, and in-depth discussion with industry experts,
manufacturers, suppliers, and distributors. The primary research participant
includes but not limited to CEO’s, Managers, Directors, VP’s, Suppliers, CSO’s, and
etc.
Secondary Research – Our research analyst performs in-depth secondary research
and extensive data mining to collect market related information through various
authentic data sources such as Annual Reports, Trade Publications, Magazines,
Research Publications, Company Press Release, and some paid data sources.
In-house Data Analysis – After extensive data mining, we perform in-house market
analysis by using various data tools, statistical methods, and data analysis tools to
arrive on a conclusion and reduce the margin of error. We provide our overviews
and market forecast for the target market after thoroughly understanding and
analyzing of collected data, historic market trends, and research outputs.
Report Delivery – Prophecy Market Insights provide report in required electronic
format (preferably in PDF format), as PDF format is easy to read and present.

Preface

Scope & Coverage
2018 2019 2020-2029
Base Year Estimated Year Forecast Years
The report considers 2018 as the base year. All calculations involving quantitative data are
based on 2018. The values represented in the report are actual values for 2018, whereas,
the values are estimated for the period 2019−2029.

Market Segmentation
Global Hereditary Angioedema Market
By Drug Class By Region
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East &
Africa
 C1 Esterase Inhibitor
 Kallikrein Inhibitor
 Bradykinin Receptor
 Attenuated Androgens
 Subcutaneous
 Intravenous
 Oral
By Route of
Administration
 Hospital Pharmacies
 Retail Pharmacies
 Online Pharmacies
By Distribution
Channels

Currency Conversion
Currency Conversion 2013-2018
The standard currency used throughout the report is USD ($). However, in the case of other currencies, the annual average currency rate
(January 1 to December 31) is used for conversion. These conversion rates are rounded to the nearest decimal place. The chart below
represents the standard conversion rates used in the report.
Currency Conversion 2013 2014 2015 2016 2017 2018
$/€ USD/EUR 0.7532 0.7535 0.8969 0.8988 0.8605 0.8566
$/£ USD/GBP 0.6395 0.6072 0.6526 0.7309 0.7607 0.7586
$/¥ USD/JPY 98.58 105.84 120.9 107.5269 113.8867 111.0019
$/₭ USD/SEK 6.5127 6.8587 8.404 8.9328 8.4135 8.8826
$/A$ USD/AUD 1.0362 1.1094 1.3112 1.343 1.3042 1.3578
$/¥ USD/RMB (CNY) 6.1905 6.1432 6.1606 6.61 6.6294 6.6675

Market Purview
Chapter 02
3
1

Executive Summary (1/5)
32
Table 2.1: Global Hereditary Angioedema Market Overview
Parameters 2019 (E) 2029 (F)
Global Hereditary Angioedema Market Value (US$ Bn) US$2.5Bn XXX.X
By Drug Class Segment with Largest Value (US$ Mn) C1 Esterase Inhibitor: XXX.X C1 Esterase Inhibitor: XXX.X
By Drug Class Segment with Highest CAGR (%)-2019-2029 XX: CAGR- XX.X
By Route of Administration Segment with Largest Value
(US$ Mn)
XX: XXX.X XX: XXX.X
By Route of Administration Segment with Highest CAGR
(%)-2019-2029
XX: CAGR- XX.X
To be Continued …

33
Table 2.2: Global Hereditary Angioedema Market Overview
Parameters 2019 (E) 2029 (F)
By Region with Largest Value (US$ Mn) North America: XXX.X North America: XXX.X
By Region with Highest CAGR (%)-2019-2029 North America: CAGR- XX.X
Key Market Players: CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst
Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead
Pharmaceuticals, Adverum Biotechnologies, and Attune
Pharmaceuticals, Inc.

34
Description
Figure 2.1: Global Hereditary Angioedema Market Value Share (%), By Drug
Class – 2019 (E)
 By drug class, the C1 Esterase segment is accounted for
major value share 61.3% in 2019. The XYZ segment is
accounted for the second highest value share XX.X% in
2019 in the target market.
Analysis
C1 Esterase
Inhibitor
Kallikrein Inhibitor
Bradykinin
Receptor
Attenuated
Androgens
XX.X%
 Hereditary angioedema is an extremely rare genetic disorder
typically characterized by edema across different parts of the
body.
 Hereditary angioedema is considered to be potentially life-
threatening and can affect from 1 in 10,000 people to 1 in
50,000 people.
 Increasing treatment options for hereditary angioedema,
increasing of diagnosis due to advances in diagnostics is
expected to boost the market.

Subcutaneous
Intravenous
Oral
XX.X%
Figure 2.2: Global Portable
Analysis and Outcome
Figure 2.2: Global Hereditary Angioedema Market Value Share (%), By Route
of Administration – 2019 (E)
Figure 2.4: Global Hereditary Angioedema Market Value Share (%), By Region –
2019 (E
Figure 2.3: Global Hereditary Angioedema Market Value Share (%), By Region
- 2019 (E)
North America
Europe
Latin America
Asia Pacific
Middle East & Africa
XX.X%
The phenomenal growth of subcutaneous injections as a mode of drug administration can be attributed to the demand for ease-of-usage
for patients, which has had an instrumental impact on the growth of this segment. Where in 2018 subcutaneous injections accounted for
close to half of the total market, by the end of the forecast period in 2027, this segment is anticipated to grow to occupy ~65% of the
share.

Opportunity Map Analysis
XXX.X
XXX.X
XXX.X
120.0
320.0
520.0
720.0
920.0
1120.0
1320.0
1520.0
1720.0
Likely Conservative Optimistic
Opportunity Map Analysis, by Market Value (US$ Mn) and
CAGR (%) Analysis and Outcome
CAGR
XX.X%
XX.X%
XX.X%
Likely
Conservative
Optimistic
Market Value (US$ Mn) - 2029

9.1%
Market at Glance
2019
2029
CAGR 2019-2029
XX.XX
US$2.5Bn

Market at Glance (2018)
North America Europe Asia Pacific Latin America Middle East & Africa
Values Hidden for Sample

Market Dynamics
Chapter 03

Market Dynamics
Drivers Restraints

Drivers (1/3)
New Therapies & Innovations Contributing to Hereditary Angioedema
 Pharmaceutical drug manufacturers are increasingly focusing on developing novel therapeutics for hereditary angioedema in order to
cater to the large unmet medical need. For instance, in August 2018, Adverum Biotechnologies, Inc. announced that it had received an
orphan drug designation from the FDA for its preclinical gene therapy product candidate ADVM-053. The grant of orphan drug
designation from the regulatory body is a positive step for ADVM-053, which is designed to be provided as single-administration for
sustained expression of C1 esterase inhibitor protein used in HAE treatment.

Drivers (2/3)
Vast patient pool with substantial medical needs
 Growing cases of hereditary angioedema (HAE) globally is a key market driver. According to the National Organization for Rare
Disorders (NORD), about 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the
condition are significantly higher due to under-reporting and misdiagnosis.

Drivers (3/3)
XXX

Restraint (1/3)
Frequent Misdiagnosis of HAE

Restraint (2/3)
XXX

Opportunity
XXX

Notable Trends
 Surge in the awareness about rare disorders and hereditary angioedema in the past few years is attributed to the growth of the global
hereditary angioedema treatment market. Novel therapies, pipeline drugs, and new product launches such as Takhzyro, a
lanadelumab monoclonal antibody for the treatment of prophylactic HAE, are the major factors driving the global hereditary angioedema
treatment market.
 The oral route of administration is emerging as a trend in the hereditary angioedema treatment market, as a majority of the pipeline
drugs are oral products. This route offers greater ease to patients and lesser side effects.
 Companies strive to enter this rare diseases market with novel products in the pipeline. These players can enter the hereditary
angioedema treatment market due to expiration of the market exclusivity of certain major products of established players in the next few
years.

Trend
Innovative treatment strategies

Trend
Development of monoclonal antibody

Trend
Improved route of administration products

Key Highlights
In August 2018,
Adverum
Biotechnologies,
Inc. announced that
it had received an
orphan drug
designation from
the FDA for its
preclinical gene
therapy product
candidate ADVM-
053
In May 2019,
BioCryst
Pharmaceuticals
announced that its
drug - BCX7353, for
the prevention of
(HAE) attacks, has
achieved its primary
endpoint for both
dose levels

Mergers and Acquisitions
On January 7, 2019,
Takeda
Pharmaceutical
Company Limited
acquired Shire plc to
form a strong value-
based,
biopharmaceutical
global leading
player.

SWOT Analysis
Global
Achondroplasia
Treatment Market
S W
O T
Strengths
Opportunities
Weakness
Threats

Pipeline Analysis (1/3)
Drugs For Hereditary Angioedema
 In recent years, there has been an impressive
amount of research being done for the
development of drugs for hereditary angioedema
treatment.
 This has included not just drugs to control the
symptoms of the illness, but also prophylactic
treatment for HAE attacks. There are currently
several drugs that are in various stages of approval
for the long-term prophylactic treatment of HAE in
children and adults.
Sample for Illustration Purpose

Key Players (1/4)
Key Players & Development
 Results of the Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment
for hereditary angioedema (HAE) attacks will be announced by August.
 The company also announced it has selected KVD824 as an oral preventive therapy for HAE. A Phase 2 trial of that medication is
scheduled for the second half of this year.
KalVista Pharmaceuticals

Drivers and Restraints Impact Analysis
Low High
Low
High
Impact on Market Value
Likely
Growth
Impact
on
Market
Growth
Rate
D1
Drivers
Restraints
XXX
Vast patient pool with substantial
medical needs
New Therapies & Innovations
Contributing to Hereditary
Angioedema
Frequent Misdiagnosis of HAE
D2
D3
R1
XXX
R2

PEST Analysis (1/4)
P
E
S
T
POLITICAL
ECONOMICAL
SOCIAL
TECHNOLOGICAL

05
Threat of New
Entrants
XX
01
02
03
Threats of
Substitutes
XX
04
Buyer Power
XX
Supplier Power
XX
Intensity of
Competitive
Rivalry
XX
PORTER’S Five Forces Analysis

Global Hereditary Angioedema Market, By
Drug Class
Chapter 04

Table 4.1: Global Hereditary Angioedema Market Value and Forecast (US$ Mn), By Drug Class - 2018–2029
Global Hereditary Angioedema Market, By Drug Class
Drug Class 2018 A 2019 E 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
C1 Esterase Inhibitor XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Kallikrein Inhibitor XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Bradykinin Receptor XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Attenuated Androgens XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Total XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X

Global Hereditary Angioedema Market, By Drug Class
Figure 4.1 : Global Hereditary Angioedema Market Value and Forecast (US$
Mn), and Y-o-Y Growth (%), By Drug Class - 2018-2029
 The global achondroplasia treatment market by was valued
US$ XXX.X Mn in 2018 and is expected to reach US$ XXX.X Mn
in 2029, and register a CAGR of XX.X% over the forecast period
 The first six year (2018-2023) cumulative value is projected to
be US$ XXX.X Mn, as compared to relatively higher cumulative
value of US$ XXX.X Mn for the last six year (2024-2029) of the
forecast period
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
-
200.0
400.0
600.0
800.0
1,000.0
1,200.0
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y
xx.x: Projected growth between 2019 and 2029

C1 Esterase Inhibitor
Figure 4.2: Global Hereditary Angioedema Market Value and Forecast (US$ Mn),
and Y-o-Y Growth (%), by C1 Esterase Inhibitor- 2018-2029 Analysis and Outcome
-1.0%
1.0%
3.0%
5.0%
-
50.0
100.0
150.0
200.0
250.0
300.0
350.0
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Kallikrein Inhibitor
Figure 4.3: Global Hereditary Angioedema Market Value and Forecast (US$
Mn), and Y-o-Y Growth (%), by Kallikrein Inhibitor- 2018-2029 Analysis and Outcome
-1.0%
1.0%
3.0%
5.0%
-
50.0
100.0
150.0
200.0
250.0
300.0
350.0
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Bradykinin Receptor
and Y-o-Y Growth (%), by Bradykinin Receptor - 2018-2029 Analysis and Outcome
-1.0%
1.0%
3.0%
5.0%
-
50.0
100.0
150.0
200.0
250.0
300.0
350.0
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Attenuated Androgens
and Y-o-Y Growth (%), by Attenuated Androgens - 2018-2029 Analysis and Outcome
-1.0%
1.0%
3.0%
5.0%
-
50.0
100.0
150.0
200.0
250.0
300.0
350.0
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Global Hereditary Angioedema Market, By
Region
Chapter 07

Region Overview
Figure 7.1: Global Hereditary Angioedema Market Value Share (%) By Region -2019
XX.X%
XX.X%
XX.X%
X.X%
XX.X%

Market Share (%) and BPS Analysis, By Region
North America
Europe
Asia Pacific
Latin America
Market
Share
in 2019
Market
Share
in 2029
Change
in BPS

Table 7.1 : Global Hereditary Angioedema Market Value and Forecast (US$ Mn), By Region - 2018–2029
Global Hereditary Angioedema Market, By Region
Region 2018 A 2019 E 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
North America XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Europe XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Asia Pacific XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Latin America XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
MEA XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X

North America
XX.X%
Market Share (%) - 2018
North America
Rest of the
World

U.S. is expected to dominate with XX.X% of market share in the year XXXX
North America
 The regional market in North America is expected to expand robustly, due to the large number of reported cases, coupled with a well-
established healthcare infrastructure. The future is set to be lucrative for manufacturers focusing on ameliorating their product
offerings to include personalized and specialty drugs for the treatment of hereditary angioedema.

North America
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
-
50.0
100.0
150.0
200.0
250.0
300.0
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y
Figure 6.2: North America Market Value and Forecast (US$ Mn),
and Y-o-Y Growth (%), 2018 – 2029
 The North America was valued at US$ XXX.X Mn in 2018
and is expected to reach US$ XXX.X Mn in 2029, and
register a CAGR of XX.X% over the forecast period.
 The first six year (2018-2023) cumulative value is projected
to be US$ XXX.X Mn, as compared to relatively higher
cumulative value of US$ XXX.X Mn for the last six year
(2024-2029) of the forecast period
 North America market value Y-o-Y growth rate is expected
to remain steady over the forecast period.
 The U.S. accounted for value share XX.X% in 2019 and is
expected to increase to XX.X % in 2029.

Table 7.2: North America Hereditary Angioedema Market Value and Forecast (US$ Mn), By Drug Class - 2018–2029
North America Hereditary Angioedema Market, By Drug Class
Source: Prophecy Market Insights To be continued ..
Drug Class 2018 A 2019 E 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
C1 Esterase Inhibitor XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Kallikrein Inhibitor XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Bradykinin Receptor XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Attenuated Androgens XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X

Table 7.3: North America Market Value and Forecast (US$ Mn), By Route of Administration, 2018 – 2029
North America Hereditary Angioedema Market, By Route of
Administration
Route of
Administratio
n
2018 A 2019 E 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
Subcutaneous XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Intravenous XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Oral XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X

Table 7.4: North America Market Value and Forecast (US$ Mn), By Distribution Channel, 2018 – 2029
North America Hereditary Angioedema Market, By Distribution
Channel
Distribution
Channel
2018 A 2019 E 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
Hospital
Pharmacies
XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Retail
Pharmacies
Online
Pharmacies

North America Hereditary Angioedema Market, By Country
Table 7.4: North America Market Value and Forecast (US$ Mn) By Country, 2018 – 2029
XXX.X
XX.X
XX.X
US Canada
Figure 7.3: North America Market Value (US$ Mn) Overview, By Country 2018 and 2029
Country 2018 A 2019 E 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
U.S. XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X
Canada XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X XX.X

Competitive Landscape
Chapter 08

Key Players
Established
Employee
Revenue
(US$ Mn)
Ticker
Competitive Snippet by Key Players
Competitive Overview

Heat Map Analysis
Company Name
Product
Drug Class 1 Drug Class 2 Drug Class 3 Drug Class 4
Key Player 1
Key Player 2
Key Player 3
Key Player 4
Key Player 5
Key Player 6
Key Player 7
Key Player 8
Key Player 9
Key Player 10
Available Not Available

80
Market Presence and Specificity Analysis
Market
Presence
Market Specificity
High
Low
High
Low

Key highlights from Major Players
 Robust R&D activities for pipeline products, new product approvals for specific indications, and strategic mergers & acquisitions are
the key strategies adopted by major players in the global hereditary angioedema treatment market.On January 7, 2019, Takeda
Pharmaceutical Company Limited acquired Shire plc to form a strong value-based, biopharmaceutical global leading player.
 In June 2017, CSL Limited launched HAEGARDA in the U.S. after strong research and development.
 In August 2018, Shire plc received FDA approval for Takhzyro, a monoclonal antibody product, in the U.S., for the treatment of
preventive hereditary angioedema.
 In January 2017, the European Commission approved Pharming Group’s Ruconest for self-administration for acute HAE attacks in
adolescents and adults.

Company Profiles
Chapter 09

CSL Behring
Company Overview Business Overview
Drug Class Portfolio
Established
Key Management
Private/Public
Headquarter
Headcount
Geographic Presence
Total Value (US$ Mn)
Value Growth (%) Over
Previous Year
Key Business Segments
Website
Source: Company Annual Reports and Website

CSL Behring
Key Highlights
February 2020: CSL
Behring Canada
announced that
HAEGARDA® (C1
Esterase Inhibitor
Subcutaneous
[Human]), is now
available in the
province of Québec.

CSL Behring
Company Financial (US$ Mn) Overview, by Year Analysis and Outcome
610
620
630
640
650
660
670
2015 2016 2017

CSL Behring
XXX
XXX
XXX
XX.X%
Figure 2.2: Global Portable
Company Share, By Drug Class
Figure 2.4: Global Hereditary Angioedema Market Value Share (%), By Region –
2019 (E
Company Share, By Region - 2019 (E)
North America
Europe
Latin America
Asia Pacific
XX.X%

Business Strategies Overview
CSL Behring
Hidden for Sample
Hidden for Sample

SWOT Analysis
CSL Behring
S W
O T
Strengths
Opportunities
Weakness
Threats

Investment Outlook
 The global hereditary angioedema treatment market is set to grow at a healthy pace during the forecast period, due to the gradually
increasing awareness and diagnoses of rare genetic diseases, and product innovation for their treatment. According to analysts, as
newer and better classes of drugs are being made for a spectrum of symptoms and severity, players targeting their R&D toward the
prophylactic treatment of hereditary angioedema attacks are likely to maximize their gains in the near future.

Future of the Market
 Surge in the awareness about rare disorders and hereditary angioedema in the past few years is attributed to the growth of the global
hereditary angioedema treatment market. Novel therapies, pipeline drugs, and new product launches such as Takhzyro, a
lanadelumab monoclonal antibody for the treatment of prophylactic HAE, are the major factors driving the global hereditary
angioedema treatment market.

Abbreviations
Abbreviation and Full Form
Abbreviation Full Form
Mn Million
Bn Billion
US$ US Dollar
CAGR Compounded Annual Growth Rate
Y-o-Y Year on Year

About Us
Copyright © PROPHECY 2019, All Rights Reserved 92
Disclaimer
 The material is based on sources which we believe are reliable, but no warranty, either expressed or implied, is provided in relation to
the accuracy or completeness of the information. The views expressed are our best judgment as of the date of issue and are subject to
change without notice. Prophecy Market Insights takes no responsibility for decisions made on the basis of these opinions.
 Any redistribution of this information is strictly prohibited. Copyright © 2019 Prophecy Market Insights pvt. Ltd , all rights reserved.
Legal and Copyright Notices
 While the editors endeavor to ensure the accuracy of all information and data contained in this Market Research Report, neither they
nor Prophecy Market Insights Pvt. Ltd. accept responsibility for any loss or damage (whether direct or indirect) whatsoever to the
customer or any third party resulting or arising there from.
 All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or
mechanical, including photocopying, recording, taping, or information storage and retrieval systems without permission of the
publisher.
Disclaimer:
Prophecy market Insights Pvt. Ltd attempts to ensure that the information provided in our market research reports is as accurate and
complete as possible, the quantity of detailed information used and the fact that some of the information (which cannot always be verified
or validated) is supplied by third parties and sources not controlled by prophecy market Insights Pvt. ltd means that we cannot always
guarantee the accuracy, completeness or originality of the information in some reports, and we are therefore not responsible for any errors
or omissions in those reports. The recipients of these reports are responsible for determining whether the information contained therein is
sufficient for use and shall use their own skill and judgement when choosing to rely upon the reports

T H A N K
YOU
To know more about us, please visit our website:
www.prophecymarketinsights.com
For sales queries or new topics email us on:
sales@prophecymarketinsights.com
For other queries contact:
Alex L
(Global Head - Business Development)
Prophecy Market Insights
964 E. Badillo Street #2042
Covina, CA 91724
Email: sales@prophecymarketinsights.com

Hereditary Angioedema Market Trends, Analysis and Forecast till 2030

Recommended

Recommended

More Related Content

Similar to Hereditary Angioedema Market Trends, Analysis and Forecast till 2030

Similar to Hereditary Angioedema Market Trends, Analysis and Forecast till 2030 (20)

More from ankitakalvankar

More from ankitakalvankar (6)

Recently uploaded

Recently uploaded (20)

Hereditary Angioedema Market Trends, Analysis and Forecast till 2030